This approach is currently being tested in clinical trials with LY260636824 in BRCA1/2 mutation associated breast or ovarian cancer, triple negative breast cancer, high grade serous ovarian cancer, metastatic castrate-resistant prostate cancer, small cell lung cancer, and paediatric solid CNS tumours. The gene discussed is BRCA1; the disease is ovarian serous adenocarcinoma.